JPH07502507A - ビスホスホネート類及び副甲状腺ホルモンを用いた骨粗鬆症の治療方法 - Google Patents

ビスホスホネート類及び副甲状腺ホルモンを用いた骨粗鬆症の治療方法

Info

Publication number
JPH07502507A
JPH07502507A JP5511155A JP51115593A JPH07502507A JP H07502507 A JPH07502507 A JP H07502507A JP 5511155 A JP5511155 A JP 5511155A JP 51115593 A JP51115593 A JP 51115593A JP H07502507 A JPH07502507 A JP H07502507A
Authority
JP
Japan
Prior art keywords
acid
parathyroid hormone
day
bisphosphonic acid
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP5511155A
Other languages
English (en)
Japanese (ja)
Inventor
ゲディス，アン　ダンバー
ボイス，ロジリー　ウェイト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Chilcott Pharmaceuticals Inc
Original Assignee
Procter and Gamble Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter and Gamble Pharmaceuticals Inc filed Critical Procter and Gamble Pharmaceuticals Inc
Publication of JPH07502507A publication Critical patent/JPH07502507A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP5511155A 1991-12-17 1992-12-15 ビスホスホネート類及び副甲状腺ホルモンを用いた骨粗鬆症の治療方法 Pending JPH07502507A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US809,620 1977-06-24
US80962091A 1991-12-17 1991-12-17
PCT/US1992/010869 WO1993011786A1 (en) 1991-12-17 1992-12-15 Methods for the treatment of osteoporosis using bisphosphonates and parathyroid hormone

Publications (1)

Publication Number Publication Date
JPH07502507A true JPH07502507A (ja) 1995-03-16

Family

ID=25201804

Family Applications (1)

Application Number Title Priority Date Filing Date
JP5511155A Pending JPH07502507A (ja) 1991-12-17 1992-12-15 ビスホスホネート類及び副甲状腺ホルモンを用いた骨粗鬆症の治療方法

Country Status (18)

Country Link
US (1) US5616560A (enExample)
EP (1) EP0618805A1 (enExample)
JP (1) JPH07502507A (enExample)
AU (2) AU3322593A (enExample)
BR (1) BR9206941A (enExample)
CA (1) CA2124792C (enExample)
CZ (1) CZ282889B6 (enExample)
FI (1) FI942884A0 (enExample)
HU (1) HUT68010A (enExample)
IL (1) IL104108A (enExample)
MA (1) MA23079A1 (enExample)
MX (1) MX9207349A (enExample)
NO (1) NO942241D0 (enExample)
NZ (1) NZ246456A (enExample)
RU (2) RU2112515C1 (enExample)
SK (1) SK74594A3 (enExample)
WO (1) WO1993011786A1 (enExample)
ZA (1) ZA929758B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002504140A (ja) * 1997-06-19 2002-02-05 アレリックス バイオファーマシューティカルズ インク． 副甲状腺ホルモンおよび骨吸収抑制剤を含む複合型薬学的製剤

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993011786A1 (en) * 1991-12-17 1993-06-24 Procter & Gamble Pharmaceuticals, Inc. Methods for the treatment of osteoporosis using bisphosphonates and parathyroid hormone
JPH08502287A (ja) * 1992-10-09 1996-03-12 ジ・アップジョン・カンパニー 抗炎症剤としてのピリミジンビスホスホン酸エステルおよび（アルコキシメチルホスフィニル）アルキルホスホン酸
FR2703590B1 (fr) 1993-04-05 1995-06-30 Sanofi Elf Utilisation de derives d'acide bisphosphonique pour la preparation de medicaments destines a favoriser la reparation osseuse .
US6013792A (en) * 1993-08-05 2000-01-11 Syntex (U.S.A.), Inc. Matrix metalloprotease inhibitors
US5496801A (en) * 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
JPH10505090A (ja) * 1994-09-09 1998-05-19 ザ、プロクター、エンド、ギャンブル、カンパニー 骨活性ホスホネート及び副甲状腺ホルモンを用いた骨粗鬆症の治療方法
KR970705399A (ko) * 1994-09-09 1997-10-09 레이셔 야코버스 코넬리스 골다공증용 포스포네이트 및 부갑상성 호르몬(phosphonates and parathyroid hormone for osteoporosis)
US5747456A (en) * 1994-12-19 1998-05-05 Beth Israel Deaconess Medical Center Continuous low-dose administration of parathyroid hormone or its agonist
CA2205959A1 (en) * 1994-12-19 1996-06-27 Michael Chorev Continuous low-dose administration of parathyroid hormone or its agonist
DE69534923T2 (de) * 1994-12-28 2006-11-23 Gador S.A. Anabolische zubereitung für knochenmasse enthaltend olpadronat
US5616571A (en) * 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
EP0891779A1 (de) * 1997-06-19 1999-01-20 Roche Diagnostics GmbH Pharmazeutische Kombinationspräparate enthaltend Parathyroidhormon und Calcium- und/oder Phosphatverbindungen
US5994329A (en) * 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6015801A (en) * 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
US6770623B1 (en) * 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
EP0922467A3 (en) * 1997-12-12 2000-05-24 Takeda Chemical Industries, Ltd. Iontophoretic drug delivery
RU2155588C2 (ru) * 1998-10-16 2000-09-10 Общество с ограниченной ответственностью "Институт фармацевтических реактивов РЕФАРМ" Способ увеличения массы костной ткани при переломах
AU1447600A (en) * 1998-10-22 2000-05-08 Thomas J. Gardella Bioactive peptides and peptide derivatives of parathyroid hormone (pth) and parathyroid hormone-related peptide (pthrp)
WO2000032771A1 (en) * 1998-11-30 2000-06-08 The General Hospital Corporation Pth1r and pth3r receptors, methods and uses thereof
SE9901572D0 (sv) * 1999-05-03 1999-05-03 Astra Ab New compounds
AUPQ232599A0 (en) * 1999-08-19 1999-09-09 Royal Alexandra Hospital For Children, The Drug for treating fractures
AU7734800A (en) * 1999-09-29 2001-04-30 General Hospital Corporation, The Polypeptide derivatives of parathyroid hormone (pth)
KR100864743B1 (ko) 2000-06-20 2008-10-22 노파르티스 아게 비스포스포네이트의 투여 방법
CA2372450A1 (en) * 2001-05-10 2001-09-19 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
KR100491737B1 (ko) * 2001-07-20 2005-05-27 주식회사 한국아이템개발 공기 정화 기능의 모기 퇴치기
US7572765B2 (en) 2001-07-23 2009-08-11 The General Hospital Corporation Conformationally constrained parathyroid hormone (PTH) analogs
JP4959917B2 (ja) * 2001-08-17 2012-06-27 ノバルティス アーゲー 副甲状腺ホルモンフラグメント用経口送達剤としての５−ｃｎａｃ
EP1494683A1 (en) * 2002-04-05 2005-01-12 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
EP2851105A1 (en) * 2002-05-10 2015-03-25 F. Hoffmann-La Roche AG Bisphosphonic acids for treatment and prevention of osteoporosis
RU2219933C1 (ru) * 2002-07-22 2003-12-27 Волова Лариса Теодоровна Способ стимуляции остеогенеза
US20040097468A1 (en) * 2002-11-20 2004-05-20 Wimalawansa Sunil J. Method of treating osteoporosis and other bone disorders with upfront loading of bisphosphonates, and kits for such treatment
AU2003220380A1 (en) * 2003-03-19 2004-11-19 Bristol-Myers Squibb Company CONFORMATIONALLY CONSTRAINED PARATHYROID HORMONES WITH Alpha-HELIX STABILIZERS
EP1635875B8 (en) * 2003-06-26 2008-12-24 pSivida Inc In-situ gelling drug delivery system
WO2005009358A2 (en) 2003-07-17 2005-02-03 The General Hospital Corporation Conformationally constrained parathyroid hormone (pth) analogs
MXPA06001428A (es) * 2003-08-06 2006-05-15 Rhodia Metodo para promover el crecimiento del hueso.
US20050043359A1 (en) * 2003-08-20 2005-02-24 The Procter & Gamble Company Kit for treatment of upper gastrointestinal tract conditions
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
RU2273493C1 (ru) * 2004-10-15 2006-04-10 Валерий Николаевич Зеленков Композиция для профилактики и лечения болезней, вызываемых дефицитом кальция (варианты)
CA2628945A1 (en) * 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US8143374B2 (en) * 2006-08-04 2012-03-27 The General Hospital Corporation Polypeptide derivatives of parathyroid hormone (PTH)
WO2008142164A2 (en) * 2007-05-24 2008-11-27 Ablynx N.V. Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
MX346714B (es) * 2007-08-01 2017-03-24 The General Hospital Corp * Metodos de analisis y seleccion usando receptores acoplados a proteina g y composiciones relacionadas.
BR112012013725A2 (pt) 2009-12-07 2017-01-10 Univ Michigan Tech paratormônio de urso preto e métodos de usar o paratormônio de uso preto.
US8882740B2 (en) * 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone
WO2011143406A2 (en) 2010-05-13 2011-11-17 The General Hospital Corporation Parathyroid hormone analogs and uses thereof
WO2016163886A2 (en) 2015-04-10 2016-10-13 Clues2Cure International B.V. Administration of taurine or an analog thereof for the treatment of nerve cell damage
CN119258199A (zh) * 2018-10-29 2025-01-07 旭化成制药株式会社 特立帕肽或其盐在骨质疏松症治疗和/或预防剂的制备中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) * 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
DE3243358A1 (de) * 1982-11-24 1984-05-24 Rolf Dieter Prof.Dr. 3004 Isernhagen Hesch Synthetisches humanes (1-38) parathormon-fragment, verfahren zu seiner herstellung und die verwendung zur behandlung der osteoporose
US4812311A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Kit for use in the treatment of osteoporosis
US4822609A (en) * 1984-12-21 1989-04-18 The Procter & Gamble Company Treatment of osteoporosis
US4812304A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Treatment of osteoporosis
IL78342A (en) * 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
US4761406A (en) * 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
US4833125A (en) * 1986-12-05 1989-05-23 The General Hospital Corporation Method of increasing bone mass
DE3935738A1 (de) * 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
WO1993011786A1 (en) * 1991-12-17 1993-06-24 Procter & Gamble Pharmaceuticals, Inc. Methods for the treatment of osteoporosis using bisphosphonates and parathyroid hormone

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002504140A (ja) * 1997-06-19 2002-02-05 アレリックス バイオファーマシューティカルズ インク． 副甲状腺ホルモンおよび骨吸収抑制剤を含む複合型薬学的製剤
JP2010100644A (ja) * 1997-06-19 2010-05-06 Nps Pharmaceuticals Inc 副甲状腺ホルモンおよび骨吸収抑制剤を含む複合型薬学的製剤
JP2014015479A (ja) * 1997-06-19 2014-01-30 Nps Pharmaceuticals Inc 副甲状腺ホルモンおよび骨吸収抑制剤を含む複合型薬学的製剤
US8765674B2 (en) 1997-06-19 2014-07-01 Nps Pharmaceuticals, Inc. Methods useful in the treatment of bone resorption diseases

Also Published As

Publication number Publication date
AU663348B2 (en) 1995-10-05
CA2124792C (en) 2000-07-04
SK74594A3 (en) 1995-01-12
NZ246456A (en) 1997-03-24
AU3322593A (en) 1993-07-19
RU2112515C1 (ru) 1998-06-10
AU3022692A (en) 1993-06-24
HUT68010A (en) 1995-05-29
CZ282889B6 (cs) 1997-11-12
US5616560A (en) 1997-04-01
MA23079A1 (fr) 1993-07-01
FI942884L (fi) 1994-06-16
EP0618805A1 (en) 1994-10-12
IL104108A0 (en) 1993-05-13
FI942884A7 (fi) 1994-06-16
FI942884A0 (fi) 1994-06-16
CA2124792A1 (en) 1993-06-24
NO942241L (enExample) 1994-08-09
NO942241D0 (no) 1994-06-15
BR9206941A (pt) 1995-05-02
WO1993011786A1 (en) 1993-06-24
IL104108A (en) 1999-09-22
ZA929758B (en) 1993-09-10
HU9401798D0 (en) 1994-09-28
CZ147794A3 (en) 1994-12-15
MX9207349A (es) 1993-12-01
RU94031209A (ru) 1996-07-27
RU2104699C1 (ru) 1998-02-20

Similar Documents

Publication Publication Date Title
JPH07502507A (ja) ビスホスホネート類及び副甲状腺ホルモンを用いた骨粗鬆症の治療方法
CA2101275C (en) Methods for the treatment of osteoporosis
JP2010106042A (ja) 骨粗鬆症の治療用のためのホスホネート類の用途
AU686458B2 (en) Methods for the treatment of osteoporosis using bone active phosphonates and parathyroid hormone
AU686019B2 (en) Phosphonates and parathyroid hormone for osteoporosis
Heys et al. Hypercalcaemia in patients with cancer: aetiology and treatment
EP3563875A1 (en) Radium for radionuclide therapy, in combination with calcium metabolism affecting treatment
Johnson et al. 2302 CYSTINE ANALOGS AS POTENTIAL THERAPEUTIC AGENTS FOR CYSTINURIA
JPH08277223A (ja) 高カルシウム血症治療のための薬剤